One hundred seventeen patients with advanced squamous cell carcinoma of the head and neck were treated and placed randomly between two combination protocols, one with adriamycin and the other without. Responses (more than 50% tumor regression) were 67% overall with 63% responding to the combination without adriamycin and 82% responding to the protocol containing it. The increase in the response rate seen with the addition of adriamycin was not statistically significant. The degree of response to chemotherapy was reduced by prior radiotherapy.
PriceLAHillBTCalvertAH: Kinetically-based multiple drug treatment for advanced head and neck cancer. Br Med J3: 10–11, 1975.
2.
PriceLAGoldieJH: Multiple drug therapy for disseminated malignant disease. Br Med J4: 336–339, 1971.
3.
HillBTBasergaR: The cell cycle and its significance for cancer treatment. Cancer Treatment Rev2: 159–175, 1975.
4.
PriceLAHillBT: A kinetically based logical approach to the chemotherapy of head and neck cancer. Clin Otolaryngol2: 339–345, 1977.
5.
BruceWRMeekerBEValerioteFA: Comparison of the sensitivity of normal haematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst37: 233–245, 1966.
6.
TattersallMHNTobiasJS: How strong is the case for intensive cancer chemotherapy?Lancet3: 1071–1072, 1976.
7.
BergsagelDE: Chemotherapy of cancer. Mod Med Can24: 19–24, 1969.
8.
PriceLA: The application of a kinetic model to clinical cancer chemotherapy, in SheddonWH, (ed): Proceedings of the Third Vinca Alkaloid Symposium. Basingstoke, Eli Lilly & Co, 1973, pp 35–40.
9.
HillBTPriceLA: Kinetic classification of antitumor drugs. Br Med J3: 367, 1975.
10.
PriceLAHillBT: Intensive cancer chemotherapy. Lancet2: 1195, 1976.
11.
AndersonGThomasGStewart-JonesJ: Treatment of advanced bronchogenic carcinoma with adriamycin, 5-fluorouracil and methotrexate. Br J Dis Chest, 71: 179–182, 1977.
12.
GoldieJHPriceLA: Twenty-hour combination chemotherapy for advanced breast cancer. Br Med J2: 1064–1065, 1977.
13.
BlumRH: An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemother Rep6: 247–252, 1975.
14.
CarterSK: Adriamycin (NSC-123127)—Thoughts for the future. Cancer Chemother Rep6: 389–398, 1975.
15.
WassermanTHComisRLGoldsmithM: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep6: 399–418, 1975.
16.
MosherMBDe ContiRDBertinoJR: Bleomycin therapy in advanced Hodgkin's disease and epidermoid cancers. Cancer30: 56–60, 1972.
17.
NerviCCasaleCCorteseM: L'iperossigenazione regionale; un importante fattore di potenziamento della chemioterapia antineoplastica. Tumori55: 153–159, 1969.
18.
HanhamIWFNewtonKAWestburyG: Seventy-five cases of solid tumors treated by a modified quadruple chemotherapy regimen. Br J Cancer25: 462–478, 1971.
19.
JacquillatCSzpirglasHWeilM: Polychimiotherapie des cancers. Etude preliminaire portant sur 82 cas, dont 76 observations de cancers d'origine stomatologique. Presse Medicale75: 1321–1324, 1967.
